Nonsurgical treatment of patent arterial duct in term neonates with congenital heart disease: the role of intravenous indomethacin

K Vandekerckhove; D Macrae; Z Slavik

doi:10.1007/s00246-004-0886-z

Nonsurgical treatment of patent arterial duct in term neonates with congenital heart disease: the role of intravenous indomethacin

Pediatr Cardiol. 2005 Sep-Oct;26(5):698-9. doi: 10.1007/s00246-004-0886-z.

Authors

K Vandekerckhove¹, D Macrae, Z Slavik

Affiliation

¹ Paediatric Intensive Care Unit, Royal Brompton Hospital, Royal Brompton & Harefield NHS Trust, Sydney Street, London SW3 6NP, UK.

PMID: 16378210
DOI: 10.1007/s00246-004-0886-z

Abstract

We present two term neonates in which intravenous indomethacin usage was associated with successful closure of a persistently patent arterial duct. Both children had congenital heart disease with high pulmonary blood flow following surgical placement of contralateral systemic-pulmonary artery shunts.

Publication types

Case Reports

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
Cyclooxygenase Inhibitors / therapeutic use
Ductus Arteriosus, Patent / drug therapy*
Heart Defects, Congenital / drug therapy
Humans
Indomethacin / therapeutic use*
Infant, Newborn
Male
Ventricular Outflow Obstruction / drug therapy

Substances

Anti-Inflammatory Agents, Non-Steroidal
Cyclooxygenase Inhibitors
Indomethacin